Dosimetric advantages of a " butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Voong, Khinh R ^a   McSpadden, Kelli ^a   Pinnix, Chelsea C ^a   Shihadeh, Ferial ^a   Reed, Valerie ^a   Salehpour, Mohammad R ^a   Arzu, Isidora ^a   Wang, He ^a   Hodgson, David ^b   Garcia, John ^a   Aristophanous, Michalis ^a   Dabaja, Bouthaina S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Hodgkin lymphoma; IMRT; Mediastinum

Indexed keywords

ARTICLE; BREAST; BREATHING FREQUENCY MONITOR; CANCER PATIENT; CLINICAL ARTICLE; DOSIMETRY; FEMALE; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LUNG; MEDIASTINUM DISEASE; PHOTON THERAPY; RADIOTHERAPY PLANNING SYSTEM; RAILWAY; SPINAL CORD; TREATMENT PLANNING; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HEART; MEDIASTINAL NEOPLASMS; ORGANS AT RISK; PATHOLOGY; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE;

BREAST; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEART; HODGKIN DISEASE; HUMANS; LUNG; MEDIASTINAL NEOPLASMS; ORGANS AT RISK; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84899994016     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-94     Document Type: Article

References (19)

1. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010, 363:640-652.
2. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, . German Hodgkin's Lymphoma Study G Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003, 21:3601-3608. German Hodgkin's Lymphoma Study G.
3. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79:270-277.
4. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004, 22:2835-2841.
5. Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Peny AM, Girinsky T, Raemaekers JM, Henry-Amar M. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. J Clin Oncol 2006, 24:3128-3135.
6. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD, Gilbert E. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290:465-475.
7. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95:971-980.
8. Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, Whitton JA, Diller L, Kenney L, Donaldson SS, Meadows AT, Neglia JP. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009, 27:3901-3907.
9. Dabaja BS, Rebueno NC, Mazloom A, Thorne S, Perrin KJ, Tolani N, Das P, Delclos ME, Iyengar P, Reed VK, Horace P, Salehpour MR. Radiation for Hodgkin's lymphoma in young female patients: a new technique to avoid the breasts and decrease the dose to the heart. Int J Radiat Oncol Biol Phys 2011, 79:503-507.
10. Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011, 79:10-18.
11. White JTA, Arthur D, Buchholz T, MacDonald S, Marks L, Pierce L, Recht A, Rabinovitch R, Taghian A, Vicini F, Woodward W, Li XA. Breast cancer atlas for radiation therapy planning: consensus definitions. Radiation therapy oncology group. 2012, Available at http://www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx (accessed July 3, 2013).
12. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys 2006, 64:333-342.
13. Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M, Xu T, Huang L, Sachs RK, Brenner DJ. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007, 110:2576-2586.
14. De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27:4239-4246.
15. Koh ES, Tran TH, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, Pintilie M, Xu T, Chung J, Paul N, Hodgson DC. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007, 2:13.
16. Sachs RK, Shuryak I, Brenner D, Fakir H, Hlatky L, Hahnfeldt P. Second cancers after fractionated radiotherapy: stochastic population dynamics effects. J Theor Biol 2007, 249:518-531.
17. Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P, Sandhu A, Culakova E, Lyman G, Mendenhall N. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 2008, 72:24-33.
18. Weber DC, Johanson S, Peguret N, Cozzi L, Olsen DR. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 2011, 81:490-497.
19. Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, Borca VC, Ragona R, Tofani S, Ricardi U. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012, 7:186.